N-(2-(4-(3-(4-Amino-5-chloro-2-methoxyphenyl)-3-oxopropyl)piperidin-1-yl)ethyl)-4-methoxybenzenesulfonamide

ID: ALA4749344

Chembl Id: CHEMBL4749344

PubChem CID: 162650788

Max Phase: Preclinical

Molecular Formula: C24H32ClN3O5S

Molecular Weight: 510.06

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(S(=O)(=O)NCCN2CCC(CCC(=O)c3cc(Cl)c(N)cc3OC)CC2)cc1

Standard InChI:  InChI=1S/C24H32ClN3O5S/c1-32-18-4-6-19(7-5-18)34(30,31)27-11-14-28-12-9-17(10-13-28)3-8-23(29)20-15-21(25)22(26)16-24(20)33-2/h4-7,15-17,27H,3,8-14,26H2,1-2H3

Standard InChI Key:  NGRQUPJYQPYJRW-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4749344

    ---

Associated Targets(Human)

HTR6 Tchem Serotonin 6 (5-HT6) receptor (9749 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

HTR4 Serotonin 4 (5-HT4) receptor (2870 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 510.06Molecular Weight (Monoisotopic): 509.1751AlogP: 3.59#Rotatable Bonds: 11
Polar Surface Area: 110.96Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 10.45CX Basic pKa: 6.95CX LogP: 2.74CX LogD: 2.61
Aromatic Rings: 2Heavy Atoms: 34QED Weighted: 0.35Np Likeness Score: -1.16

References

1. Yahiaoui S,Hamidouche K,Ballandonne C,Davis A,de Oliveira Santos JS,Freret T,Boulouard M,Rochais C,Dallemagne P.  (2016)  Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.,  121  [PMID:27266998] [10.1016/j.ejmech.2016.05.048]

Source